重大事件
即時報告
8-K
2026-07-02
CorMedix任命Elizabeth Hurlburt為首席運營及商務官 推動商業化整合
AI 繁中摘要
CorMedix Inc.（納斯達克：CRMD）於2026年6月29日提交8-K申報，披露高層管理架構變動。公司董事會任命現任首席運營官Elizabeth Hurlburt為新設立的「首席運營及商務官」（Chief Operating and Commercial Officer），統領所有商業職能，同時亦負責醫學事務、法規及臨床工作。Hurlburt將繼續向董事長兼行政總裁Joseph Todisco匯報。與此同時，Michael Seckler已離開公司。📋
是次重組反映CorMedix正加強商業化及營運整合，尤其在公司核心產品Defencath（預防血液透析患者導管相關血流感染）上市及推廣的關鍵階段。投資者可留意新管理層能否加快產品滲透及監管進展。管理層暫未有其他具體展望。整體而言，人事變動屬正常企業策略調整，短期影響有限，但長遠或提升執行效率。
展開英文正文
crmd-20260629FALSE000141009800014100982026-06-292026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2026 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware001-3467320-5894890 (State of other jurisdiction of incorporation or organization) (Commission File Number)(I.R.S. Employer Identification No.) 389 Interpace Parkway, Suite 450 Parsippany, NJ 07054 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: (908) 517-9500 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2, below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, $0.001 par valueCRMDNasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01 Other Events. On June 29, 2026, CorMedix Inc. (the “Company”) effected a change in its executive leadership structure, whereby the Company’s Board of Directors has appointed Elizabeth Hurlburt, currently the Chief Operating Officer, to the newly created role of Chief Operating and Commercial Officer where she will have functional oversight of all commercial functions in addition to medical affairs, regulatory and clinical. Ms. Hurlburt will continue to report to Chairman & CEO Joseph Todisco in this newly created role. As part of this change in executive leadership structure, Michael Seckler has left the Company. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORMEDIX INC. Date: July 2, 2026By:/s/ Joseph Todisco Name:Joseph Todisco Title:Chief Executive Officer